Please login to the form below
alemtuzumab
This page shows the latest alemtuzumab news and features for those working in and with pharma, biotech and healthcare.
Sanofi highlights MS drug data as it swings to a loss in Q4
For 2019 as a whole it topped 2.1bn in sales. Sanofi already has an established MS franchise with oral therapy Aubagio (teriflunomide) and Lemtrada (alemtuzumab), but that declined 3% to
Latest news
-
Novartis’ Mayzent and Roche’s Polivy lead CHMP recommendations
This includes Sanofi Genzyme’s multiple sclerosis medicine Lemtrada(alemtuzumab), which now has restricted use due to reports of rare but serious side effects, including death.
-
Sanofi settles Lemtrada dispute with Genzyme investors for $315m
The dispute centres on Lemtrada (alemtuzumab) and specifically the regulatory and sales milestone payments that were due Genzyme shareholders as part of Sanofi’s $20bn takeover of Genzyme in 2011, when
-
After some big setbacks, Sanofi talks up its R&D portfolio
It also has high hopes for alemtuzumab in primary progressive MS, Regeneron-partnered cemiplimab for first-line non-small cell lung cancer and SAR425899, a GLP-1/GCR dual agonist that
-
NICE backtracks on Biogen's multiple sclerosis drug Zinbryta
the disease if they have failed to respond to first-line treatment with Sanofi's Lemtrada (alemtuzumab) or have rapidly evolving severe MS.
-
Mylan buys into six biosimilars, including Orencia candidate
Prolia/Xgeva (denosumab) and Vectibix (panitumumab), Novartis' Xolair (omalizumab) and Sanofi's Campath (alemtuzumab), according to Evercore ISI analyst Umer Raffat.
More from news
Approximately 7 fully matching, plus 25 partially matching documents found.
Latest appointments
-
Executive changes at Sanofi
such as Aubagio (teriflunomide) and Lemtrada (alemtuzumab).
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Associate Account Director
-
Competitive Salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Senior Medical Writer
-
Competitive Salary
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
-
Medical Editor
-
Competitive Salary
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
-
Senior Account Executive
-
Competitive Salary
-
Account Management
-
Competitive Salary Offered
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Account Manager
-
Competitive Salary
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
-
Publications Director
-
Competitive Salary
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- Merck & Co reveals plans for women’s health spinoff Organon
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- bluebird bio aiming to separate business units by year-end
- AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER
- Sharing patient stories for World Pulmonary Hypertension Day
- AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- China’s Sinopharm given WHO emergency use listing for COVID-19 vaccine
- Pfizer, BioNTech file for full US approval of COVID-19 vaccine
- The impact of cancer on mental health during COVID-19
- Moderna agrees to supply Gavi with 500 million doses for COVAX
- The new reality of building a corporate brand in pharma
- Why female mentorship is so powerful in pharma
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- Lilly’s RET inhibitor Retevmo shows early promise in new cancer types
- Amgen adds Otezla to the COVID-19 candidate list
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- Sharing patient stories for World Pulmonary Hypertension Day
- For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...
- How nature can help you manage the pressures of agency life
- Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
- How can we strike the right balance between familiarity and innovation when it comes to data presentation?
- Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
